Neuropsychiatry, Royal Melbourne Hospital


Neuropsychiatry team portal:

Publications: Full list on PubMed

the Markers in Neuropsychiatric Disorders (MiND) study

The Seminars in Neuropsychiatry has moved to:


Click here for the full list of publications on PubMed (currently only first author displays below, unfortunately)

  • by Nicholas M Burgess
    CONCLUSIONS: This study demonstrated improvements in cognitive function, anxiety, and depression ratings associated with resumption of dietary control of PKU. Raw Phe levels were not strongly associated with psychiatric or cognitive scores in this cohort. These findings support the importance of lifelong treatment for PKU in improving the cognitive and psychiatric sequelae of the disease.
  • by Yew Li Dang
    OBJECTIVE: Adverse events (AEs) related to antiepileptic drugs (AEDs) may interfere with adequate dosing and patient adherence, leading to suboptimal seizure control, and relatedly, increased injuries, hospitalizations, and mortality. This study investigated the clinicodemographic factors associated with AEs related to AEDs as reported by the Liverpool Adverse Events Profile (LAEP), and explored the ability of LAEP to discriminate between epilepsy and psychogenic nonepileptic seizures (PNES). We…
  • by Roxane Dilcher
    CONCLUSION: The NUCOG differentiated cognitive profiles in patients with uncontrolled seizures due to different etiologies. Bilateral TLE and medication adversely affected cognitive performance, and overall patients with epilepsy performed worse than those with nonepileptic seizures. These results provide further evidence for sensitivity of the NUCOG for detecting cognitive impairment in patients with seizure disorders.
  • by Dhamidhu Eratne
    Currently there is no secured ongoing funding in Australia for next generation sequencing (NGS) such as exome sequencing (ES) for adult neurological disorders. Studies have focused on paediatric populations in research or highly specialised settings, utilised standard NGS pipelines focusing only on small insertions, deletions and single nucleotide variants, and not explored impacts on management in detail. This prospective multi-site study performed ES and an extended bioinformatics repeat…
  • by Lucy Vivash
    INTRODUCTION: Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment. Previous work by our group has shown sodium selenate upregulates the activity of protein phosphatase 2 in the brain, increasing the rate of tau dephosphorylation. The objective of this study is to evaluate the efficacy and safety of sodium…
  • by David Trainor
    OBJECTIVE: Epilepsy and psychogenic nonepileptic seizures (PNES) are serious conditions, associated with substantial morbidity and mortality. Although prompt diagnosis is essential, these conditions are frequently misdiagnosed, delaying appropriate treatment. We developed and validated the Anxiety, Abuse, and Somatization Questionnaire (AASQ), a quick and clinically practical tool to differentiate PNES from epilepsy.
  • by Hui Guo
    NCKAP1/NAP1 regulates neuronal cytoskeletal dynamics and is essential for neuronal differentiation in the developing brain. Deleterious variants in NCKAP1 have been identified in individuals with autism spectrum disorder (ASD) and intellectual disability; however, its clinical significance remains unclear. To determine its significance, we assemble genotype and phenotype data for 21 affected individuals from 20 unrelated families with predicted deleterious variants in NCKAP1. This includes 16…
  • by Eliana Brehaut
    CONCLUSIONS: HADS-D ≥8 substantially overestimates depression prevalence. Of all possible cutoff thresholds, HADS-D ≥11 was closest to the SCID, but there was substantial heterogeneity in the difference between HADS-D ≥11 and SCID-based estimates. HADS-D should not be used as a substitute for a validated diagnostic interview.
  • by Christos Pantelis
    Although COVID-19 is predominantly a respiratory disease, it is known to affect multiple organ systems. In this article, we highlight the impact of SARS-CoV-2 (the coronavirus causing COVID-19) on the central nervous system as there is an urgent need to understand the longitudinal impacts of COVID-19 on brain function, behaviour and cognition. Furthermore, we address the possibility of intergenerational impacts of COVID-19 on the brain, potentially via both maternal and paternal routes. Evidence…
  • by Samantha M Loi
    CONCLUSIONS: This study reports on the largest cohort of YOD to date, with diagnostic breakdown similar to previous retrospective file reviews. The neuropsychiatry service is funded to follow-up its patients, thus allowing re-assessment and continuity of care. While there are limitations in this study such as the lack of neuropathological outcomes, the findings emphasise the strengths of follow-up and appropriate service provision for these patients.

See more

Neuropsychiatry, Royal Melbourne Hospital:

Please click here to complete the Seminars in Neuropsychiatry survey

RMH-Alfred-Concord Seminars in Neuropsychiatry

Unfortunately due to COVID-19 and the rapidly evolving situation and impacts this has had at our main lecture sites, we have had to cancel/postpone the 13 April talk by Dr Chris Kyndt. We plan to resume on 12 May, but in a purely ‘virtual’ setting, with lectures delivered and attended via Zoom. Please do not hesitate to contact us if we can clarify anything. We hope you are managing as best as you can and looking after yourselves and others, during these challenging times.

Neuropsychiatry at the Royal Melbourne, Alfred and Concord Hospitals are pleased to have several seminars planned for 2020. Please spread the word to colleagues far and wide with this link:

To receive details on how to attend sessions, for any queries, feedback, to suggest potential future topics, and to be put on the email list, please contact us.

Save the dates for these upcoming seminars (Melbourne time):
8-9am (Melbourne time) on the following Tuesdays:

14 April: Dr Chris Kyndt: autoimmune encephalitis postponed to 1 December

12 May: Professor Perminder Sachdev: DSM-5 classification of neurocognitive disorders

14 July: A/Professor David Darby: cognitive assessment

1 September: Dr Ramon Mocellin:  ‘The Perfect Storm’: Neuropsychiatry of Parkinson’s Disease

13 October: Professor Julian Trollor: Autism in adulthood: what future psychiatrists should know about assessment and management

1 December: Dr Chris Kyndt: autoimmune encephalitis

Please click here to access slides and other materials from previous seminars.

Kind regards,
Dr Dhamidhu Eratne
Dr Toby Winton-Brown
Dr Andrew Gleason
Professor Dennis Velakoulis


Contact us


Thank you

We hope you’ve enjoyed our RMH-Alfred Neuropsychiatry Education Series this year, and we look forward to seeing you next year.

– Dhamidhu Eratne, Toby Winton-Brown, Dennis Velakoulis, and many others, on behalf of the Section of Neuropsychiatry and Royal Melbourne Hospital and the Alfred

Thank you to all our excellent speakers for their time, and special mention and thanks to Kate Egan, Nicholas Burgess, and Lily Ward for keeping the lecture series afloat.

Please keep in touch via and updated via

Now it’s feedback time!

Please go to this website to give us some (anonymous) feedback:

Genetics in Neurodegenerative Disorders Symposium

This research and clinically focussed event promises to offer a broad overview of current issues in genetics in neurodegenerative disorders, and should be of interest to a wide range of clinicians, researchers and scientists in the neurosciences.

Ticketing has been reopened!

Register now via this Eventbrite link:

Please contact Dr Dhamidhu Eratne ( if you have any queries.

Programme and Speakers:

Monday 12 August, 1400-1730
Venue TBC at MCRI/RCH – trying to get larger venue

1400-1500 Glenda Halliday (confirmed) – opening plenary – “Overview of neurodegenerative genetics and why NGS is needed”

1500-1520 (15min + 5min for questions) Dhamidhu Eratne (confirmed) – “WES, What is it Good for (in Neurodegenerative Disorders)? Updates from the Melbourne Genomics Complex Neurology Flagship” 

1520-1540 (15min + 5min for questions) Martin Delatycki and David Szmulewicz (confirmed) – “Genetic ataxia- what is the latest about aetiology and treatment?”

1540-1600Coffee break

1600-1620 (15min + 5min for questions) Aamira Huq (confirmed) – “The Paradox of the Young Demented and the Old Resilient – Can Genetics Explain?”

1620-1640 (15min + 5min for questions) Melanie Bahlo (confirmed) – “Repeat Expansion Detection from NGS Data for Neurodegenerative Disorders”

1640-1700 (15min + 5min for questions) Sam Berkovic (confirmed) – “Genetics in Epilepsy”

1700-1730 (20-25 + 5-10min for questions) Steve Petrou (confirmed) – “The Promise of Antisense Oligonucleotide Therapy in Neurogenetic Disorders”